ゼリア新薬工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2025/08/22 | 2,065 | 2,077 | 2,062 | 2,072 | +9 | +0.4% | 59,200 |
2025/08/21 | 2,060 | 2,067 | 2,049 | 2,063 | -1 | ±0% | 103,200 |
2025/08/20 | 2,065 | 2,085 | 2,061 | 2,064 | +11 | +0.5% | 70,200 |
2025/08/19 | 2,040 | 2,053 | 2,033 | 2,053 | +22 | +1.1% | 70,300 |
2025/08/18 | 2,023 | 2,042 | 2,023 | 2,031 | +10 | +0.5% | 58,400 |
2025/08/15 | 2,039 | 2,039 | 2,018 | 2,021 | -17 | -0.8% | 81,000 |
2025/08/14 | 2,030 | 2,049 | 2,021 | 2,038 | +6 | +0.3% | 92,400 |
2025/08/13 | 2,036 | 2,043 | 2,027 | 2,032 | +3 | +0.1% | 105,000 |
2025/08/12 | 2,034 | 2,048 | 2,021 | 2,029 | +5 | +0.2% | 125,100 |
2025/08/08 | 2,024 | 2,035 | 2,018 | 2,024 | +5 | +0.2% | 117,800 |
2025/08/07 | 2,028 | 2,040 | 2,003 | 2,019 | +8 | +0.4% | 169,600 |
2025/08/06 | 1,991 | 2,029 | 1,972 | 2,011 | -84 | -4% | 401,500 |
2025/08/05 | 2,110 | 2,113 | 2,092 | 2,095 | -5 | -0.2% | 65,500 |
2025/08/04 | 2,100 | 2,110 | 2,087 | 2,100 | -17 | -0.8% | 60,100 |
2025/08/01 | 2,115 | 2,129 | 2,100 | 2,117 | +25 | +1.2% | 62,500 |
2025/07/31 | 2,081 | 2,105 | 2,077 | 2,092 | +8 | +0.4% | 67,600 |
2025/07/30 | 2,075 | 2,085 | 2,065 | 2,084 | -1 | ±0% | 57,800 |
2025/07/29 | 2,060 | 2,085 | 2,057 | 2,085 | +25 | +1.2% | 82,700 |
2025/07/28 | 2,065 | 2,073 | 2,055 | 2,060 | +4 | +0.2% | 49,300 |
2025/07/25 | 2,062 | 2,069 | 2,053 | 2,056 | -13 | -0.6% | 60,800 |
2025/07/24 | 2,075 | 2,081 | 2,069 | 2,069 | +3 | +0.1% | 59,700 |
2025/07/23 | 2,062 | 2,068 | 2,047 | 2,066 | +22 | +1.1% | 62,900 |
2025/07/22 | 2,065 | 2,067 | 2,044 | 2,044 | -22 | -1.1% | 44,000 |
2025/07/18 | 2,085 | 2,087 | 2,066 | 2,066 | -18 | -0.9% | 33,800 |
2025/07/17 | 2,070 | 2,084 | 2,064 | 2,084 | +13 | +0.6% | 31,400 |
2025/07/16 | 2,063 | 2,080 | 2,063 | 2,071 | +9 | +0.4% | 39,300 |
2025/07/15 | 2,063 | 2,082 | 2,062 | 2,062 | +1 | ±0% | 31,400 |
2025/07/14 | 2,043 | 2,076 | 2,043 | 2,061 | +10 | +0.5% | 46,400 |
2025/07/11 | 2,057 | 2,071 | 2,049 | 2,051 | +9 | +0.4% | 36,700 |
2025/07/10 | 2,056 | 2,061 | 2,034 | 2,042 | -11 | -0.5% | 61,700 |
2025/07/09 | 2,043 | 2,060 | 2,039 | 2,053 | +27 | +1.3% | 57,200 |
2025/07/08 | 2,033 | 2,043 | 2,018 | 2,026 | -12 | -0.6% | 84,600 |
2025/07/07 | 2,042 | 2,055 | 2,036 | 2,038 | -4 | -0.2% | 33,000 |
2025/07/04 | 2,055 | 2,062 | 2,041 | 2,042 | -4 | -0.2% | 44,200 |
2025/07/03 | 2,050 | 2,063 | 2,036 | 2,046 | +4 | +0.2% | 52,600 |
2025/07/02 | 2,041 | 2,055 | 2,036 | 2,042 | -7 | -0.3% | 48,600 |
2025/07/01 | 2,075 | 2,085 | 2,048 | 2,049 | -36 | -1.7% | 53,200 |
2025/06/30 | 2,094 | 2,108 | 2,085 | 2,085 | -4 | -0.2% | 74,400 |
2025/06/27 | 2,090 | 2,094 | 2,074 | 2,089 | +10 | +0.5% | 80,600 |
2025/06/26 | 2,080 | 2,096 | 2,071 | 2,079 | +8 | +0.4% | 63,800 |
2025/06/25 | 2,069 | 2,072 | 2,036 | 2,071 | +15 | +0.7% | 77,200 |
2025/06/24 | 2,064 | 2,082 | 2,037 | 2,056 | +19 | +0.9% | 78,800 |
2025/06/23 | 2,046 | 2,048 | 2,032 | 2,037 | -11 | -0.5% | 49,100 |
2025/06/20 | 2,013 | 2,048 | 2,007 | 2,048 | +26 | +1.3% | 259,600 |
2025/06/19 | 2,026 | 2,036 | 2,013 | 2,022 | -17 | -0.8% | 65,100 |
2025/06/18 | 2,024 | 2,048 | 2,024 | 2,039 | +8 | +0.4% | 46,700 |
2025/06/17 | 2,020 | 2,041 | 2,020 | 2,031 | +10 | +0.5% | 52,900 |
2025/06/16 | 2,054 | 2,058 | 2,021 | 2,021 | -17 | -0.8% | 52,200 |
2025/06/13 | 2,060 | 2,064 | 2,023 | 2,038 | -30 | -1.5% | 98,500 |
2025/06/12 | 2,068 | 2,076 | 2,057 | 2,068 | -3 | -0.1% | 60,400 |
1~
50
件表示中 / 3768件
類似銘柄と比較する
現在ご覧いただいている「ゼリア新薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ゼリア新薬 | 206,700円 | +3.1% | -6.5% | 2.32% | 9.59倍 | 1.02倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ジーエヌアイ | 277,500円 | +21.7% | +999.9% | 0.00% | 12.78倍 | 4.38倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
持田薬 | 320,500円 | +5.1% | -7.0% | 2.50% | 21.04倍 | 0.87倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
杏林製薬 | 156,300円 | -2.4% | -52.3% | 3.65% | 18.71倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 239,900円 | +4.1% | -3.1% | 2.42% | 20.84倍 | 1.81倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム